BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 8970508)

  • 1. Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT.
    Pirker W; Riedl M; Luger A; Czech T; Rössler K; Asenbaum S; Angelberger P; Kornhuber J; Deecke L; Podreka I; Brücke T
    J Nucl Med; 1996 Dec; 37(12):1931-7. PubMed ID: 8970508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of iodine-123 epidepride and iodine-123 IBZM for dopamine D2 receptor imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas.
    de Herder WW; Reijs AE; de Swart J; Kaandorp Y; Lamberts SW; Krenning EP; Kwekkeboom DJ
    Eur J Nucl Med; 1999 Jan; 26(1):46-50. PubMed ID: 9933661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand.
    de Herder WW; Reijs AE; Kwekkeboom DJ; Hofland LJ; Nobels FR; Oei HY; Krenning EP; Lamberts SW
    Clin Endocrinol (Oxf); 1996 Dec; 45(6):755-67. PubMed ID: 9039343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease.
    Pirker W; Asenbaum S; Wenger S; Kornhuber J; Angelberger P; Deecke L; Podreka I; Brücke T
    J Nucl Med; 1997 Nov; 38(11):1711-7. PubMed ID: 9374338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.
    Ferone D; Lastoria S; Colao A; Varrella P; Cerbone G; Acampa W; Merola B; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 1998 Jan; 83(1):248-52. PubMed ID: 9435450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging?
    de Herder WW; Reijs AE; Feelders RA; van Aken MO; Krenning EP; Tanghe HL; van der Lely AJ; Kwekkeboom DJ
    Eur J Endocrinol; 2006 Nov; 155(5):717-23. PubMed ID: 17062888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iodine-123-IBZM-SPECT: studies in 15 patients with pituitary tumors.
    Pirker W; Brücke T; Riedl M; Clodi M; Luger A; Asenbaum S; Podreka I; Deecke L
    J Neural Transm Gen Sect; 1994; 97(3):235-44. PubMed ID: 7873131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Graphical analysis and simplified quantification of striatal and extrastriatal dopamine D2 receptor binding with [123I]epidepride SPECT.
    Ichise M; Fujita M; Seibyl JP; Verhoeff NP; Baldwin RM; Zoghbi SS; Rajeevan N; Charney DS; Innis RB
    J Nucl Med; 1999 Nov; 40(11):1902-12. PubMed ID: 10565788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single photon emission computed tomography scan study of striatal dopamine D2 receptor binding with 123I-epidepride in patients with schizophrenia and controls.
    Tibbo P; Silverstone PH; McEwan AJ; Scott J; Joshua A; Golberg K
    J Psychiatry Neurosci; 1997 Jan; 22(1):39-45. PubMed ID: 9002391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Test-retest reproducibility of extrastriatal dopamine D2 receptor imaging with [123I]epidepride SPECT in humans.
    Varrone A; Fujita M; Verhoeff NP; Zoghbi SS; Baldwin RM; Rajeevan N; Charney DS; Seibyl JP; Innis RB
    J Nucl Med; 2000 Aug; 41(8):1343-51. PubMed ID: 10945525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of iodine-123-epidepride and iodine-123-IBZM for dopamine D2 receptor imaging.
    Leslie WD; Abrams DN; Greenberg CR; Hobson D
    J Nucl Med; 1996 Oct; 37(10):1589-91. PubMed ID: 8862288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of pituitary adenomas].
    Mezosi E; Nemes O
    Orv Hetil; 2009 Sep; 150(39):1803-10. PubMed ID: 19758960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbon-11 epidepride: a suitable radioligand for PET investigation of striatal and extrastriatal dopamine D2 receptors.
    Langer O; Halldin C; Dollé F; Swahn CG; Olsson H; Karlsson P; Hall H; Sandell J; Lundkvist C; Vaufrey F; Loc'h C; Crouzel C; Mazière B; Farde L
    Nucl Med Biol; 1999 Jul; 26(5):509-18. PubMed ID: 10473189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical application of 11C-NMSP to the patients with pituitary adenoma other than prolactinoma].
    Momose T; Teramoto A; Nishikawa J; Inoue Y; Watanabe T; Sasaki Y
    Kaku Igaku; 1993 Jun; 30(6):627-35. PubMed ID: 8345693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Striatal and extrastriatal imaging of dopamine D2 receptors in the living human brain with [123I]epidepride single-photon emission tomography.
    Kuikka JT; Akerman KK; Hiltunen J; Bergström KA; Räsänen P; Vanninen E; Halldin C; Tiihonen J
    Eur J Nucl Med; 1997 May; 24(5):483-7. PubMed ID: 9142727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic imaging of dopamine receptors in pituitary adenomas.
    de Herder WW; Reijs AEM; Feelders RA; van Aken MO; Krenning EP; van der Lely AJ; Kwekkeboom DJ
    Eur J Endocrinol; 2007 Apr; 156 Suppl 1():S53-S56. PubMed ID: 17413189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [123I]epidepride binding to cerebellar dopamine D2/D3 receptors is displaceable: implications for the use of cerebellum as a reference region.
    Pinborg LH; Videbaek C; Ziebell M; Mackeprang T; Friberg L; Rasmussen H; Knudsen GM; Glenthoj BY
    Neuroimage; 2007 Feb; 34(4):1450-3. PubMed ID: 17175177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes.
    Hierholzer J; Cordes M; Venz S; Schelosky L; Harisch C; Richter W; Keske U; Hosten N; Mäurer J; Poewe W; Felix R
    J Nucl Med; 1998 Jun; 39(6):954-60. PubMed ID: 9627325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo characterization of R(+)-FIDA2: a dopamine D2-like imaging agent.
    Vessotskie JM; Kung MP; Chumpradit S; Romaniello G; McElgin W; Frederick D; Malison RT; Kung HF
    J Nucl Med; 1995 Jul; 36(7):1282-8. PubMed ID: 7790957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.